STE

Business profile & competitive position

STERIS plc (STE) operates in the Healthcare sector, specifically the Medical - Specialties industry. The company is a global provider of healthcare and life-science products and services concentrated on infection prevention and patient care. Its revenue streams include consumables such as detergents, endoscopy accessories, instruments, and barrier products; capital equipment such as sterilizers, surgical tables, and automated endoscope reprocessors; and a wide range of services that cover equipment installation and maintenance, instrument and scope repair, laboratory testing, microbial reduction, outsourced reprocessing, and operating-room connectivity solutions.

STERIS reports through three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Following the fiscal 2025 divestiture of the Dental segment, Dental is now treated as discontinued operations, leaving the three infection-prevention-focused segments as the core of the business.

The company’s reported profitability gives some context on its competitive position: a 13.3% net margin and an 11.3% return on equity. Those figures indicate STERIS is consistently profitable and converting shareholder equity into a low-double-digit return, though they do not by themselves establish that its competitive moat is widening or narrowing. The installed base of sterilization and endoscopy equipment, combined with recurring consumables and service attach, is a common source of stability in this industry, and the margin profile suggests that mix is currently holding up.

Financial posture

At the time of the data snapshot, STERIS carried a market capitalization of $22.4 billion and traded at a trailing P/E of 28.0. A P/E in the high-20s typically embeds an expectation of durable growth and stable cash flows, especially for a healthcare supplier. The current price was $229.75, with the 50-day exponential moving average at $222.82 and the RSI at 53.6, which is essentially neutral territory.

Besides valuation, the profitability metrics are notable. Net margin is 13.3% and ROE is 11.3%. The stock’s beta is 0.91, meaning it has historically moved slightly less than the broader equity market—consistent with a defensive, healthcare-oriented revenue base. No debt figure was supplied in this snapshot, so the commentary here is limited to the valuation and profitability data that were provided: the company is profitable, reasonably valued relative to its margin profile, and slightly less volatile than the overall market.

Strategic priorities & outlook

STERIS’s most recent 10-K outlines four operational priorities. First, it plans to keep expanding irradiation processing capacity using accelerator-based technologies, a direct hedge against potential disruption in cobalt-60 supply for its Applied Sterilization Technologies segment. Second, the company is applying Lean and continuous-improvement principles across manufacturing, service operations, back-office functions, and support processes with the goal of driving efficiency. Third, STERIS explicitly treats acquisitions as a key component of its long-term growth strategy. Fourth, it has committed to near-term company-wide emissions reductions and is preparing disclosures aligned with CSRD/ESRS and TCFD ESG frameworks.

The filing also contained operational details that support execution visibility. In fiscal 2026, no single customer represented more than 10% of revenue in any of the Healthcare, AST, or Life Sciences segments, which reduces customer-concentration risk. Capital-equipment backlog stood at $490.7 million at March 31, 2026, up from $452.9 million at March 31, 2025, with the increase driven by shipment timing and acquisitions. The regulatory track record was clean: no FDA or other regulatory enforcement actions, zero products listed in the FDA MedWatch Safety Alerts database, and no Class I recalls in fiscal 2026, 2025, or 2024.

Macro & geopolitical exposure

Because STERIS sits in Healthcare / Medical - Specialties, its exposures are largely industry-typical rather than company-specific. Regulatory oversight is a constant: FDA rules, infection-prevention standards, and recall protocols all matter for sterilization devices, surgical equipment, and consumables. Any tightening of safety standards or premarket requirements would flow through this industry.

Trade policy and tariffs can affect capital equipment and single-use consumables that cross borders, while supply-chain risks show up in areas such as cobalt-60 sourcing and accelerator hardware. Currency translation is relevant for a “global provider,” since overseas revenues and costs convert back into reporting currency. Commodity and energy prices feed into sterilization operations and manufacturing, and hospital capital-spending cycles plus reimbursement pressures influence demand for large-ticket sterilizers and surgical tables. ESG reporting exposure is also present, given the company’s stated preparation for CSRD/ESRS and TCFD-aligned disclosures.

Recent developments

STERIS reported fiscal Q1 2027 results on August 5, 2026. The company posted actual EPS of $2.59 against an estimate of $2.49, a 4% earnings surprise to the upside. Revenue, however, missed expectations, which is why the aftermarket reaction was soft. The stock fell 0.4% the next trading day but drifted 1.67% higher over the following five sessions.

The news flow around the report was concentrated in early August. Seeking Alpha published the Q1 2027 earnings call transcript on August 6, 2026. The same day, Zacks ran a headline noting that STE beat earnings estimates but missed on revenue, with the stock dipping in aftermarket trading. MarketBeat and Defenseworld followed with Q1 earnings call highlights on August 9 and August 11, 2026, respectively.

Relative to current technical levels, the stock is trading above its 50-day EMA of $222.82 with an RSI of 53.6, suggesting neither overbought nor oversold conditions immediately after the mid-August reporting cluster.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, STERIS has beaten earnings estimates five times, for a beat rate of 71%. The average earnings surprise across those quarters was 2.2%. In the five trading days following each report, the stock has averaged a move of 2.36%, classified as an upward post-earnings drift.

The most recent four quarters illustrate how much individual reports can deviate from that average. On August 5, 2026, a 4% EPS beat produced a modest next-day decline of 0.4% but a 1.67% gain over five days. On May 11, 2026, STERIS narrowly missed estimates with actual EPS of $2.83 versus $2.85, yet the stock jumped 4.46% the next day and 5.46% over five days. February 4, 2026, was a flat result—actual EPS of $2.53 exactly matched the estimate—but the market punished the stock, sending it down 7.74% the next day and 7.87% over the following five days. By contrast, the November 5, 2025 report showed a 5.1% beat, a 6.94% next-day rally, and a 10.2% five-day advance.

The takeaway is that the aggregate trend is upward drift, but the path is uneven. Revenue misses and inline quarters can override the positive EPS surprise, and next-day reactions do not always predict the subsequent five-day move. The next scheduled report is November 4, 2026, after the close, with a consensus EPS estimate of $2.68.

For a deeper dive into institutional sentiment on STERIS—including model assumptions, rating distributions, and the full fundamental verdict—review the complete institutional analysis rather than relying on headline numbers alone.